{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Ribeiro RM"],"funding":["NIAID NIH HHS","NHLBI NIH HHS","NIH","NIH HHS"],"pagination":["S136-S143"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10469346"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["228(Suppl 2)"],"pubmed_abstract":["Understanding variant-specific differences in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral kinetics may explain differences in transmission efficiency and provide insights on pathogenesis and prevention. We evaluated SARS-CoV-2 kinetics from nasal swabs across multiple variants (Alpha, Delta, Epsilon, Gamma) in placebo recipients of the ACTIV-2/A5401 trial. Delta variant infection led to the highest maximum viral load and shortest time from symptom onset to viral load peak. There were no significant differences in time to viral clearance across the variants. Viral decline was biphasic with first- and second-phase decays having half-lives of 11 hours and 2.5 days, respectively, with differences among variants, especially in the second phase. These results suggest that "],"journal":["The Journal of infectious diseases"],"pubmed_title":["Variant-Specific Viral Kinetics in Acute COVID-19."],"pmcid":["PMC10469346"],"funding_grant_id":["UM1 AI069412","UM1 AI106701","U01 AI068636","UM1 AI069423","R01-HL143541);","UM1 AI069424","UM1 AI068634","UM1 AI068636","U01 AI069463","U01 AI069424","U54 HL143541","UM1 AI069463"],"pubmed_authors":["Cooper M","ACTIV-2/A5401 Study Team","Ribeiro RM","Chew KW","Perelson AS","Murtaugh W","Deo R","Eron JJ","Patel N","Currier JS","Giganti MJ","Greninger AL","Flynn JP","Aldrovandi G","Hosey L","Science F","Erhardt B","Knowles K","Moser C","Ritz J","Li JZ","Smith DM","Wohl DA","Adams S","Daar ES","Roa J","Choudhary MC","Regan J","Gutzman H","Hughes MD","Bowman R"],"additional_accession":[]},"is_claimable":false,"name":"Variant-Specific Viral Kinetics in Acute COVID-19.","description":"Understanding variant-specific differences in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral kinetics may explain differences in transmission efficiency and provide insights on pathogenesis and prevention. We evaluated SARS-CoV-2 kinetics from nasal swabs across multiple variants (Alpha, Delta, Epsilon, Gamma) in placebo recipients of the ACTIV-2/A5401 trial. Delta variant infection led to the highest maximum viral load and shortest time from symptom onset to viral load peak. There were no significant differences in time to viral clearance across the variants. Viral decline was biphasic with first- and second-phase decays having half-lives of 11 hours and 2.5 days, respectively, with differences among variants, especially in the second phase. These results suggest that ","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Aug","modification":"2026-06-01T19:37:26.712Z","creation":"2025-04-04T10:38:48.744Z"},"accession":"S-EPMC10469346","cross_references":{"pubmed":["37650233"],"doi":["10.1093/infdis/jiad314"]}}